Generating new drug repurposing hypotheses using disease-specific hypergraphs.

Q2 Computer Science
Ayush Jain, Marie Charpignon, Irene Y. Chen, Anthony Philippakis, Ahmed Alaa
{"title":"Generating new drug repurposing hypotheses using disease-specific hypergraphs.","authors":"Ayush Jain, Marie Charpignon, Irene Y. Chen, Anthony Philippakis, Ahmed Alaa","doi":"10.1142/9789811286421_0021","DOIUrl":null,"url":null,"abstract":"The drug development pipeline for a new compound can last 10-20 years and cost over $10 billion. Drug repurposing offers a more time- and cost-effective alternative. Computational approaches based on network graph representations, comprising a mixture of disease nodes and their interactions, have recently yielded new drug repurposing hypotheses, including suitable candidates for COVID-19. However, these interactomes remain aggregate by design and often lack disease specificity. This dilution of information may affect the relevance of drug node embeddings to a particular disease, the resulting drug-disease and drug-drug similarity scores, and therefore our ability to identify new targets or drug synergies. To address this problem, we propose constructing and learning disease-specific hypergraphs in which hyperedges encode biological pathways of various lengths. We use a modified node2vec algorithm to generate pathway embeddings. We evaluate our hypergraph's ability to find repurposing targets for an incurable but prevalent disease, Alzheimer's disease (AD), and compare our ranked-ordered recommendations to those derived from a state-of-the-art knowledge graph, the multiscale interactome. Using our method, we successfully identified 7 promising repurposing candidates for AD that were ranked as unlikely repurposing targets by the multiscale interactome but for which the existing literature provides supporting evidence. Additionally, our drug repositioning suggestions are accompanied by explanations, eliciting plausible biological pathways. In the future, we plan on scaling our proposed method to 800+ diseases, combining single-disease hypergraphs into multi-disease hypergraphs to account for subpopulations with risk factors or encode a given patient's comorbidities to formulate personalized repurposing recommendations.Supplementary materials and code: https://github.com/ayujain04/psb_supplement.","PeriodicalId":34954,"journal":{"name":"Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing","volume":"53 19","pages":"261-275"},"PeriodicalIF":0.0000,"publicationDate":"2023-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1142/9789811286421_0021","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Computer Science","Score":null,"Total":0}
引用次数: 0

Abstract

The drug development pipeline for a new compound can last 10-20 years and cost over $10 billion. Drug repurposing offers a more time- and cost-effective alternative. Computational approaches based on network graph representations, comprising a mixture of disease nodes and their interactions, have recently yielded new drug repurposing hypotheses, including suitable candidates for COVID-19. However, these interactomes remain aggregate by design and often lack disease specificity. This dilution of information may affect the relevance of drug node embeddings to a particular disease, the resulting drug-disease and drug-drug similarity scores, and therefore our ability to identify new targets or drug synergies. To address this problem, we propose constructing and learning disease-specific hypergraphs in which hyperedges encode biological pathways of various lengths. We use a modified node2vec algorithm to generate pathway embeddings. We evaluate our hypergraph's ability to find repurposing targets for an incurable but prevalent disease, Alzheimer's disease (AD), and compare our ranked-ordered recommendations to those derived from a state-of-the-art knowledge graph, the multiscale interactome. Using our method, we successfully identified 7 promising repurposing candidates for AD that were ranked as unlikely repurposing targets by the multiscale interactome but for which the existing literature provides supporting evidence. Additionally, our drug repositioning suggestions are accompanied by explanations, eliciting plausible biological pathways. In the future, we plan on scaling our proposed method to 800+ diseases, combining single-disease hypergraphs into multi-disease hypergraphs to account for subpopulations with risk factors or encode a given patient's comorbidities to formulate personalized repurposing recommendations.Supplementary materials and code: https://github.com/ayujain04/psb_supplement.
利用特定疾病超图生成新的药物再利用假设。
一种新化合物的药物开发周期可能长达 10-20 年,耗资超过 100 亿美元。药物再利用提供了一种时间更短、成本效益更高的替代方案。基于由疾病节点及其相互作用组成的网络图表示的计算方法最近产生了新的药物再利用假说,包括 COVID-19 的合适候选药物。然而,这些相互作用组的设计仍然是聚合的,往往缺乏疾病特异性。这种信息稀释可能会影响药物节点嵌入与特定疾病的相关性、由此产生的药物-疾病和药物-药物相似性得分,从而影响我们识别新靶点或药物协同作用的能力。为了解决这个问题,我们提出了构建和学习特定疾病超图的建议,其中超图编码了不同长度的生物通路。我们使用改进的 node2vec 算法生成路径嵌入。我们评估了我们的超图为阿尔茨海默病(AD)这一无法治愈但普遍存在的疾病寻找再利用目标的能力,并将我们的排序推荐与从最先进的知识图谱--多尺度交互组--中得出的推荐进行了比较。利用我们的方法,我们成功地发现了 7 种有希望重新成为治疗阿尔茨海默病目标的候选药物,这些候选药物在多尺度相互作用组中被列为不可能重新成为目标的药物,但现有文献为其提供了支持性证据。此外,我们的药物重新定位建议还附有解释,引出了合理的生物学途径。未来,我们计划将我们提出的方法推广到800多种疾病,将单病种超图结合到多病种超图中,以考虑具有风险因素的亚人群或编码特定患者的合并症,从而制定个性化的再利用建议。补充材料和代码:https://github.com/ayujain04/psb_supplement。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
4.50
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信